← Back to the studies fieldPERMANENT CTIS TRIAL DOSSIER

2025-523264-21-00

CIRAANO: Multimodal exploration of theater actors, memory athletes, and patients with various memory pathologies: evaluation of mnesic strategies and their cerebral substrates, and contribution to the treatment of memory pathologies.

Public registry stateAuthorised

CLAIM BOUNDARY

This dossier documents a medicinal trial—not proof of efficacy.

Registration, authorisation of a trial application, trial start, result disclosure and marketing authorisation are different facts. The dossier claims neither clinical efficacy nor safety, deployment or causality.

CTIS record ≠ efficacy ≠ marketing authorisation

REGISTRY FACTS

What CTIS publishes about this trial

EUCT number: 2025-523264-21-00
Trial status: Authorised
Sponsor: not published
Trial region: EEA
Phase: 10
Trial category: 2
Low-intervention trial: no
Estimated EU start: 04 June 2026
Decision date: 23 January 2026
Published: 06 June 2026
Estimated end: 01 March 2036

EXACT AI EVIDENCE

The original text determines inclusion.

Terms count only in allowlisted public CTIS fields. Sponsor, medical condition, phase or a generic software reference alone is not AI evidence.

“…pography of brain pathology and the factors influencing its propagation over 10 to 20 years, in both controls and patients, with the aim of predicting disease progression using an artificial intelligence model”

Source field: authorizedApplication.authorizedPartI.trialDetails.trialInformation.trialObjective.secondaryObjectives[5].secondaryObjective
Matched term: artificial intelligence

MEDICAL CONTEXT

Conditions and therapeutic areas

Reported medical conditions

Semantic Variant Primary Progressive Aphasia
Alcohol Use Disorder
Organic amnesia syndrome
Narcolepsy
Alzheimer
Lewy Body Dementia

Therapeutic areas

Psychiatry and Psychology [F] - Mental Disorders [F03]33
Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Investigative Techniques [E05]28
Diseases [C] - Pathological Conditions, Signs and Symptoms [C23]23

COUNTRY TRACKS

Every country retains its own published state.

A status in one country is not transferred to another. Decision dates and status histories remain separate source facts.

France

Authorised

First decision: 23 January 2026
Latest decision: 23 January 2026

23 January 2026Authorised
23 January 2026Authorised

TRIAL APPLICATIONS

Submission, decision and country state remain separate

INITIAL

Authorised

Trial status: Authorised
Submitted: 10 October 2025
Decided: 23 January 2026

Decisions23 January 2026 · Authorized

Country statusFrance · Authorised

SOURCE-DATED CHRONICLE

Official dates, not an efficacy narrative.

The chronicle sorts published CTIS events. i6eal observation times follow on a separate clock.

10 October 2025Application Submitted
Application IN · Authorised
20 January 2026Country Assessment
France · Application IN · Authorized
23 January 2026Application Status
Application IN · Authorised
23 January 2026Country Decision
France · Application IN · Authorized
23 July 2026Trial Status Observed
Authorised

Observed by i6eal

First observed: 23 Jul 2026, 13:19
Last observed: 23 Jul 2026, 15:03
Materially modified: 23 July 2026

RESULT DISCLOSURE

Disclosure is a separate registry fact.

No result disclosure is published in this projection. This means neither that results do not exist nor that a deadline has been missed.

PROVENANCE

From the dossier back to the official record

The public CTIS record remains authoritative. The i6eal files are a deterministic, bounded projection.

Open public CTIS record ↗Open CTIS retrieval source ↗Machine-readable dossier · JSON ↓Structured metadata · JSON-LD ↓

i6eal (2026): EU AI Studies Monitor, CTIS trial 2025-523264-21-00, data state 23 July 2026. https://i6eal.de/en/tools/ki-studienmonitor/studie/2025-523264-21-00/